# Niraparib and Dostarlimab in HRD Solid Tumors

> **NCT04983745** · PHASE2 · UNKNOWN · sponsor: **West Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Homologous Recombination Deficient Solid Tumors

## Interventions

- **DRUG:** Combination drug

## Key facts

- **NCT ID:** NCT04983745
- **Lead sponsor:** West Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-29
- **Primary completion:** 2024-08
- **Final completion:** 2025-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983745, "Niraparib and Dostarlimab in HRD Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04983745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*